CD274 and myelodysplastic syndrome: Finally, and importantly, these data suggest that anti-PD-1 or anti-PD-L1 blocking antibodies, alone or in combination with other strategies, offer therapeutic promise in MDS to improve the BM microenvironment and restore effective hematopoiesis.